{"podcast":{"title":"Metabolic Mind","slug":"metabolic-mind-6253550","podcast_index_feed_id":6253550,"rss_url":"https://feeds.captivate.fm/metabolic-mind/","website_url":"https://metabolicmind.org/","image_url":"https://artwork.captivate.fm/d5c870fb-4d35-464f-8bde-33ce9e2b58c4/MM-Podcast-cover-final.png","author":"Bret Scher","episode_count":224,"summary":"Metabolic Mind is working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. Metabolic interventions like ketogenic therapy are being used to treat serious mental illnesses like Bipolar Disorder, Schizophrenia, and Major Depressive Disorder. We explore topics that can help you understand how Metabolic Psychiatry might help you or a loved one treat mental disorders Watch our videos at https://www.youtube.com/@metabolicmind Our channel is for information only. Consult your physician before changing your lifestyle or medications.","last_synced_at":"2026-07-24T00:18:08.497488+00:00","page_url":"https://stenobird.com/podcast/metabolic-mind-6253550"},"episode":{"title":"GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals","slug":"glp-1s-and-cardiovascular-risk-what-the-latest-evidence-reveals","published_at":"2026-04-22T15:05:00+00:00","page_url":"https://stenobird.com/podcast/metabolic-mind-6253550/glp-1s-and-cardiovascular-risk-what-the-latest-evidence-reveals","show_page_url":"https://stenobird.com/podcast/metabolic-mind-6253550","url":"https://metabolicmind.org/","audio_url":"https://episodes.captivate.fm/episode/b1135ea2-d5b0-424f-9862-6e67ba1729bd.mp3","summary":"GLP-1 receptor agonists like semaglutide are often described as “game changers” for weight loss and cardiovascular health, and in many ways, the data support that claim. Clinical trials suggest meaningful reductions in major cardiovascular events, offering hope for individuals struggling with metabolic disease. But there’s an important nuance that deserves more attention: what happens when these medications are stopped? In this conversation, Dr. Bret Scher explores emerging real-world data showing that the benefits of GLP-1s, particularly for cardiovascular risk, appear to depend on continued use. For many individuals, stopping the medication leads to a reversal of progress, raising important questions about long-term strategy, sustainability, and what true metabolic healing looks like. Are we managing symptoms, or addressing root causes? What role should medications play in long-term care? How can we use powerful tools like GLP-1s to support , rather than replace, sustainable metabolic change? For some individuals, long-term use may be appropriate and beneficial. But we need to broaden the conversation toward approaches that aim to improve underlying metabolic health, support lasting behavior change, and ultimately reduce reliance on lifelong interventions when possible. If you’re exploring GLP-1s or are currently taking one, consider speaking with your healthcare provider about how to pair your treatment with sustainable lifestyle strategies such as nutrition, physical activity, and metabolic support, to help maintain progress over time. 👉 How do GLP-1 medications impact mental health? Learn more on our blog: Ozempic, Wegovy, and Mental Health: Are GLP-1 Drugs Linked to Suicidal Thoughts? 🔎 Have questions about how to apply metabolic therapies effectively? Submit the…","meta_description":"GLP-1 receptor agonists like semaglutide are often described as “game changers” for weight loss and cardiovascular health, and in many ways, the data supp…","key_points":[],"chapters":[],"topics":[],"duration_seconds":452,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/metabolic-mind-6253550/episodes/glp-1s-and-cardiovascular-risk-what-the-latest-evidence-reveals/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/metabolic-mind-6253550/glp-1s-and-cardiovascular-risk-what-the-latest-evidence-reveals.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}